28
Views
3
CrossRef citations to date
0
Altmetric
Research Article

A comparison between once-daily and twice-daily administration of metoprolol in the management of hypertension

Pages 85-90 | Received 06 May 1980, Published online: 11 Aug 2008
 

Summary

The efficacy of metoprolol as an antihypertensive agent was assessed in 20 previously untreated Asian patients with mild to moderate hypertension. After a 4-week run-in period when placebo therapy was given, the patients were given oral metoprolol at a starting dosage of 100 mg twice daily. The dosage of metoprolol was increased at fortnightly intervals until either satisfactory blood pressure control, defined as a diastolic blood pressure of less than 90 mmHg or a greater than 10% fall in pre-treatment diastolic blood pressure, was achieved or a total of 400 mg metoprolol was reached. All 20 patients had satisfactory control of their blood pressures on a twice-daily regimen and the average dosage of metoprolol required was 200 mg daily. For the second part of the study, the medication was changed to a once-daily regimen at the same total dosage of metoprolol. Final efficacy of once-daily therapy was assessed after 8 weeks of treatment. All blood pressure and pulse rate reductions were significant (p<0.001) from the placebo phase. However, twice-daily and once-daily readings were not significantly different from each other. No side-effects were reported during the study.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.